By Michael Susin


AstraZeneca's prostate-cancer treatment Lynparza has been approved in Japan, while Soliris has been approved for expanded use to treat generalized myasthenia gravis, the company said Thursday.

The Anglo-Swedish pharma giant said Lynparza, which is being jointly developed with Merck & Co., has been approved in combination with abiraterone and prednisolone for the treatment of metastatic castration-resistant prostate cancer.

The approval was based on a late-stage study, which showed that the combination reduced the risk of disease progression or death by 77% when compared with the abiraterone treatment alone.

In a separate statement, AstraZeneca said Soliris has been approved in Japan to be used for the treatment of generalized myasthenia gravis in pediatric patients under certain conditions.

The treatment is the first and only targeted therapy approved for the treatment of children and adolescents with the condition in the country.


Write to Michael Susin at


(END) Dow Jones Newswires

August 24, 2023 02:43 ET (06:43 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Da Nov 2023 a Dic 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Da Dic 2022 a Dic 2023 Clicca qui per i Grafici di Astrazeneca